Nephrology Division, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.
Semin Dial. 2020 Nov;33(6):457-463. doi: 10.1111/sdi.12922. Epub 2020 Oct 8.
Vascular access is the Achilles heel for hemodialysis (HD). An arteriovenous fistula (AVF), considered the optimal access for HD, rather than a graft or central venous catheter (CVC) caused the "Fistula First" initiative to dominate quality assessment. However, this initiative had the unintended consequence of increasing the proportion of less desirable catheters, leading to "Fistula First, Catheter Last". But as the end-stage kidney disease (ESKD) population expanded with aging, sicker patients, individual assessment of the appropriate access changed the paradigm to KDOQI's "Patient First: ESKD Life-Plan" to attain the "right access, in the right patient, at the right time, for the right reasons". However, such a goal has proved elusive because the optimal vascular access does not currently exist. Thus, ESKD care providers attempting to offer the "right access" must weigh the barriers to achieving the most optimal access to suit each of their HD patients. The barriers are based on shortcomings related specifically to each of the three vascular accesses and to characteristics of each ESKD patient's demographics, physical factors, quality of life, and cost considerations. This article will describe these barriers so that clinicians caring for ESKD patients initiating or receiving HD provide the most optimal vascular access for that specific patient.
血管通路是血液透析(HD)的致命弱点。动静脉瘘(AVF)被认为是 HD 的最佳通路,而不是移植物或中心静脉导管(CVC),这导致了“瘘管优先”倡议主导质量评估。然而,这一倡议产生了意想不到的后果,增加了不太理想的导管的比例,导致了“瘘管优先,导管最后”。但是,随着终末期肾病(ESKD)患者的老龄化、病情加重,个体评估适当的通路改变了 KDOQI 的“患者优先:ESKD 生活计划”范式,以实现“正确的通路,在正确的患者,在正确的时间,出于正确的原因”。然而,由于目前还没有最佳的血管通路,这样的目标仍然难以实现。因此,试图提供“正确通路”的 ESKD 护理提供者必须权衡实现最优化通路的障碍,以适应每个 HD 患者的情况。这些障碍是基于与三种血管通路相关的缺陷,以及每个 ESKD 患者的人口统计学、身体因素、生活质量和成本考虑因素的特点。本文将描述这些障碍,以便为开始接受或正在接受 HD 的 ESKD 患者提供护理的临床医生为该特定患者提供最佳的血管通路。